The screening identified ABT-737, a B-cell lymphoma (BCL)-family inhibitor and Purvalanol A, a CDK2 inhibitor, as a combination with therapeutic potential for MLL-rearranged leukemia and internal tandem duplications of the fms-related tyrosine kinase 3 gene (FLT3-ITD). This evidence concerns the gene KMT2A and leukemia.